TY  - JOUR
AU  - Melisi, Davide
AU  - García Carbonero, Rocío
PY  - 2021
DO  - 10.1136/jitc-2020-002068
SN  - 2051-1426
UR  - https://hdl.handle.net/20.500.14352/117184
T2  - Journal for ImmunoTherapy of Cancer
AB  - BackgroundWe assessed the safety, efficacy, and pharmacokinetics of the transforming growth factor beta (TGFβ) receptor inhibitor galunisertib co-administered with the anti-programmed death-ligand 1 (PD-L1) antibody durvalumab in recurrent/refractory...
LA  - eng
PB  - BMJ Publishing Group
TI  - Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
TY  - journal article
VL  - 9
ER  -